HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark W Dewhirst Selected Research

AEOL 10150

9/2011Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics.
11/2007Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 protects lungs from fractionated radiation.
2/2007Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark W Dewhirst Research Topics

Disease

181Neoplasms (Cancer)
03/2022 - 05/2002
53Hypoxia (Hypoxemia)
03/2022 - 04/2002
47Hyperthermia
03/2022 - 03/2003
35Breast Neoplasms (Breast Cancer)
01/2021 - 09/2002
19Carcinoma (Carcinomatosis)
01/2022 - 07/2003
19Neoplasm Metastasis (Metastasis)
10/2018 - 03/2003
13Sarcoma (Soft Tissue Sarcoma)
03/2022 - 07/2005
7Prostatic Neoplasms (Prostate Cancer)
01/2019 - 03/2003
6Melanoma (Melanoma, Malignant)
01/2022 - 01/2006
6Necrosis
01/2021 - 02/2005
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/2013 - 12/2004
6Lung Injury
11/2007 - 09/2002
5Glioma (Gliomas)
06/2015 - 11/2005
5Adenocarcinoma
12/2008 - 03/2003
5Fibrosarcoma
01/2007 - 09/2004
4Fibrosis (Cirrhosis)
01/2017 - 11/2003
4Brain Neoplasms (Brain Tumor)
01/2016 - 02/2011
4Glioblastoma (Glioblastoma Multiforme)
01/2016 - 12/2006
4Urinary Bladder Neoplasms (Bladder Cancer)
05/2014 - 03/2012
4Inflammation (Inflammations)
04/2011 - 12/2006
3Hepatocellular Carcinoma (Hepatoma)
12/2019 - 07/2013
3Inflammatory Breast Neoplasms
04/2017 - 02/2012
3Head and Neck Neoplasms (Head and Neck Cancer)
01/2017 - 11/2015
3Wounds and Injuries (Trauma)
07/2010 - 02/2003
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2010 - 12/2008
2Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2020 - 01/2016
2Radiation Injuries (Radiation Sickness)
11/2015 - 09/2011
2Ovarian Neoplasms (Ovarian Cancer)
10/2015 - 11/2008

Drug/Important Bio-Agent (IBA)

33Pharmaceutical PreparationsIBA
03/2022 - 04/2002
32Oxygen (Dioxygen)IBA
12/2020 - 04/2002
17Proteins (Proteins, Gene)FDA Link
01/2022 - 03/2003
17Doxorubicin (Adriamycin)FDA LinkGeneric
10/2018 - 10/2004
17Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2016 - 02/2004
16Glucose (Dextrose)FDA LinkGeneric
01/2019 - 01/2003
15Hemoglobins (Hemoglobin)IBA
01/2019 - 05/2002
13Liposomes (Liposome)IBA
07/2013 - 06/2004
12CytokinesIBA
10/2013 - 09/2002
9Biological ProductsIBA
12/2020 - 12/2005
8ManganeseIBA
01/2021 - 10/2005
8PorphyrinsIBA
01/2021 - 10/2005
8Lactic Acid (Lactate)FDA LinkGeneric
04/2016 - 06/2005
7liposomal doxorubicin (Doxil)FDA Link
11/2021 - 02/2006
7Contrast MediaIBA
09/2017 - 06/2004
6AntioxidantsIBA
09/2011 - 02/2007
6Paclitaxel (Taxol)FDA LinkGeneric
12/2010 - 07/2004
6pimonidazoleIBA
10/2009 - 04/2002
6Carbonic Anhydrase IXIBA
02/2008 - 06/2004
5DNA (Deoxyribonucleic Acid)IBA
01/2022 - 01/2006
5Reactive Oxygen Species (Oxygen Radicals)IBA
12/2020 - 06/2007
5Cisplatin (Platino)FDA LinkGeneric
01/2017 - 07/2003
5Biomarkers (Surrogate Marker)IBA
11/2015 - 02/2008
4Temozolomide (Temodar)FDA LinkGeneric
01/2016 - 01/2006
4Mitomycin (Mitomycin-C)FDA LinkGeneric
01/2016 - 03/2012
4Superoxide DismutaseIBA
11/2015 - 11/2003
4Hypoxia-Inducible Factor 1IBA
06/2015 - 06/2008
4Alkylating AgentsIBA
02/2015 - 09/2004
4Phosphotransferases (Kinase)IBA
05/2013 - 03/2003
4Interleukin-12 (IL 12)IBA
07/2008 - 03/2006
4ErythropoietinFDA Link
06/2007 - 10/2003
3PolymersIBA
01/2021 - 09/2009
3Indicators and Reagents (Reagents)IBA
01/2020 - 11/2003
3Matrix Metalloproteinases (MMPs)IBA
07/2018 - 09/2005
3Messenger RNA (mRNA)IBA
01/2017 - 01/2007
3Therapeutic UsesIBA
01/2017 - 08/2013
3Mn(III) meso- tetrakis(N- n- butoxyethylpyridinium- 2- yl)porphyrinIBA
01/2016 - 01/2015
3Melphalan (Alkeran)FDA LinkGeneric
02/2015 - 01/2006
3bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
07/2014 - 01/2005
3Coloring Agents (Dyes)IBA
06/2012 - 05/2008
3LigandsIBA
10/2011 - 01/2004
3AEOL 10150IBA
09/2011 - 02/2007
3Lysophosphatidylcholines (Lysophosphatidylcholine)IBA
01/2010 - 10/2004
3Transcription Factors (Transcription Factor)IBA
12/2008 - 06/2007
3LuciferasesIBA
12/2008 - 08/2004
3Free RadicalsIBA
06/2008 - 05/2004
3Green Fluorescent ProteinsIBA
05/2008 - 09/2002
3Nucleotide AptamersIBA
05/2008 - 04/2003
3FibrinIBA
02/2005 - 03/2003
2Ethanol (Ethyl Alcohol)IBA
01/2021 - 01/2017
2BoronIBA
11/2020 - 09/2010
2Ficusin (Psoralen)IBA
01/2020 - 01/2016
2Cadherins (E-Cadherin)IBA
01/2019 - 02/2015
2Deoxyglucose (2 Deoxy D glucose)IBA
07/2018 - 03/2013
2salicylhydroxamic acid (SHAM)IBA
11/2017 - 09/2009
2MicellesIBA
09/2017 - 10/2011
2CathepsinsIBA
01/2017 - 11/2015
2Death Domain ReceptorsIBA
01/2017 - 11/2015
2Radiation-Sensitizing AgentsIBA
11/2015 - 08/2005
2RNA (Ribonucleic Acid)IBA
11/2015 - 06/2015
2Phenobarbital (Luminal)FDA Link
11/2015 - 06/2011

Therapy/Procedure

59Therapeutics
01/2021 - 03/2003
49Radiotherapy
03/2022 - 05/2002
33Drug Therapy (Chemotherapy)
03/2022 - 07/2003
10Aftercare (After-Treatment)
01/2022 - 11/2003
7Neoadjuvant Therapy
06/2015 - 11/2003
7Induced Hyperthermia (Thermotherapy)
08/2014 - 03/2003
4Immunotherapy
01/2022 - 10/2013
3Catheters
05/2014 - 01/2007
3Microelectrodes
01/2008 - 09/2004
3Lasers (Laser)
05/2007 - 05/2005
2Chemoradiotherapy
01/2016 - 02/2011